P2RX6 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5847070	0.91	1/20
SCHEMBL4563043	0.89	1/20
SCHEMBL5613282	0.89	1/20
SCHEMBL30181339	0.89	1/20
SCHEMBL5848925	0.81	1/20
SCHEMBL5847412	0.81	1/20
SCHEMBL1441797	0.79	1/20
SCHEMBL3682844	0.79	1/20
SCHEMBL19248226	0.79	1/20
SCHEMBL19255493	0.79	1/20
SCHEMBL29381827	0.79	1/20
SCHEMBL29810828	0.78	1/20
SCHEMBL26882842	0.74	1/20
SCHEMBL26882927	0.74	1/20
SCHEMBL26883083	0.74	1/20
SCHEMBL31677495	0.74	1/20
SCHEMBL23300501	0.74	1/20
SCHEMBL29524069	0.73	1/20
SCHEMBL31677489	0.73	1/20
SCHEMBL5847211	0.73	1/20

Clinical trials — most relevant to P2RX6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine	PHASE4	COMPLETED
Add-on Cangrelor in STEMI-triggered Cardiac Arrest	PHASE4	UNKNOWN
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel	PHASE4	COMPLETED
PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment	PHASE4	COMPLETED
Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks	PHASE3	WITHDRAWN
Botulinum Toxin Injections for Oral Neuropathic Pain	PHASE3	COMPLETED
Clopidogrel and Response Variability Investigation Study 2	PHASE3	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.	PHASE2	NOT_YET_RECRUITING
First Time in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food of Single Assending Doses of GSK1482160.	PHASE1	COMPLETED
A Safety Study Of A Single Vaginal Administration Of P2G12 Antibody In Healthy Female Subjects	PHASE1	COMPLETED
A Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of HS-10383	PHASE1	UNKNOWN
Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults	EARLY_PHASE1	COMPLETED
Functional Magnetic Resonance Imaging of ATP Cough in Chronic Cough Patients	nan	COMPLETED
Neuroinflammatory Interactions of ATP and P2X3 Receptor in the Airways of Chronic Cough Patients	nan	RECRUITING
Caffeine vs. ALA in BMS Treatment. (BMS: Burning Mouth Syndrome. ALA: Alpha-Lipoic Acid.)	nan	COMPLETED
An Investigation Into the Mechanism of Inhalation Cough Challenge	nan	COMPLETED
Suppressive Functions of Regulatory T Cells in Migraine	nan	NOT_YET_RECRUITING
Neurogenic Mechanisms in Burning Mouth Syndrome	nan	COMPLETED
Local Injection of Botulinium Toxin-A in Children With Dysfunctional Voiding or Refractory Nocturnal Eneuresis	nan	RECRUITING
In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors	nan	COMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment	nan	NOT_YET_RECRUITING
Developing a Method to Objectively Measure Opioid Analgesia	nan	ACTIVE_NOT_RECRUITING
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain.	nan	UNKNOWN
Effect of Botulinum Toxin A on Neurogenic Detrusor Overactivity in Chronic Spinal Cord Injured Patients	nan	COMPLETED
Exploring the Genetics of Neuropathic Pain	nan	RECRUITING
Cytokines in Papillon-Lefèvre Syndrome	nan	COMPLETED
Poor Sleep and Inflammation in HIV-Infected Adults	nan	COMPLETED
The Role of Urinary ATP in the Diagnosis, Treatment, and Follow-up of Children With Overactive Bladder	nan	COMPLETED
Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a P2RX6 binder may also engage these)

Protein	Name	Similarity
O54803	—	0.995	O54803 →
P51579	—	0.993	P51579 →
P2RX5	P2X purinoceptor 5	0.991	landscape →
Q5M936	—	0.986	Q5M936 →
P49654	—	0.984	P49654 →
INSRR	Insulin receptor-related protein	0.983	landscape →
Q9BDK6	—	0.983	Q9BDK6 →
Q64663	—	0.983	Q64663 →
Q6IWH7	—	0.982	Q6IWH7 →
Q9Z1M0	—	0.982	Q9Z1M0 →
A4IFL1	—	0.982	A4IFL1 →
Q90830	—	0.982	Q90830 →
Q9Y264	—	0.981	Q9Y264 →
Q91VE2	—	0.981	Q91VE2 →
Q7M734	—	0.980	Q7M734 →
Q5E9U1	—	0.980	Q5E9U1 →
P2RX1	P2X purinoceptor 1	0.980	landscape →
O43278	—	0.980	O43278 →
P36380	—	0.980	P36380 →
P70671	—	0.980	P70671 →
Q9TTK6	—	0.980	Q9TTK6 →
IL4I1	L-amino-acid oxidase	0.979	landscape →
B2BS84	—	0.979	B2BS84 →
P2RX3	P2X purinoceptor 3	0.979	landscape →
Q96PB7	—	0.979	Q96PB7 →
O75064	—	0.979	O75064 →
Q2KJ22	—	0.979	Q2KJ22 →
Q00978	—	0.979	Q00978 →
ENGASE	Cytosolic endo-beta-N-acetylglucosaminidase	0.978	landscape →
O95477	—	0.978	O95477 →